Widespread use of the Pap test for cervical cancer screening has dramatically reduced cervical cancer incidence and mortality rates. The knowledge about optimal use of cervical cancer screening has evolved these last year and conducted to improve new cervical prevention. The American College of Obstetricians and Gynecologists (ACOG) recommend that cervical cancer screening should not begin before the age 21 years and that screening tests should be performed at less frequent intervals. CA 125 is considered to be the best test to detect relapse among women previously treated for ovarian cancer. However, a recent randomized trial has reported that there is no benefice to initiate the therapy before presence of symptoms. In 2009, the FIGO published a revised staging for cervical, endometrial and vulvar cancer to improve prognostic disease and therapy decision.